Intelligence Profile
Research Papers
The available research on hexarelin spans several therapeutic areas, though clinical trial evidence remains limited. The compound has been studied primarily in preclinical models and laboratory settings.
Neuroprotective Effects
Recent laboratory studies suggest hexarelin may have protective effects in neurological conditions. A 2023 study published in the International Journal of Molecular Sciences examined hexarelin's effects in human neuroblastoma cells expressing a mutated protein associated with amyotrophic lateral sclerosis (ALS). Additionally, research published in the Indian Journal of Pharmacology in 2026 investigated hexarelin's ability to promote survival of retinal ganglion cells after optic nerve injury, suggesting potential applications in eye diseases involving nerve damage.
Kidney Protection
A 2023 study in the European Journal of Medical Research examined hexarelin's effects on acute kidney injury caused by reduced blood flow. The researchers found that hexarelin appeared to reduce cell death through a specific molecular pathway (MDM2/p53), suggesting potential kidney-protective properties in ischemic conditions.
Cardiovascular Research
Research published in Frontiers in Physiology in 2021 used advanced synchrotron radiation imaging techniques to study hexarelin's actions in the heart of small animal models, though specific findings were not detailed in the available abstracts.
Drug Development and Detection
More recent research has focused on understanding hexarelin's metabolism and detection. A 2025 study in the Journal of Analytical Toxicology worked on identifying biomarkers for a related compound (alexamorelin) using human liver cell studies. Additionally, a 2023 study in Nanoscale examined how peptide drugs like hexarelin interact with substances that help drug absorption in the intestine.
Performance Enhancement Context
A 2026 review in Frontiers in Endocrinology discussed hexarelin within the broader landscape of performance-enhancing peptides that affect growth hormone pathways, highlighting the gap between limited clinical evidence and widespread self-administration by users.
Limitations
No completed clinical trials were identified in the available evidence, indicating that research remains primarily at the preclinical stage. The available studies are largely laboratory-based or conducted in animal models, limiting direct applicability to human clinical use.
This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.